Na Cocer Peptides 
hashize iminsi 29
INGINGO ZOSE N'AMAKURU Y’IBICURUZWA BITANZWE KURI URU RUBUGA BISANZWE KUBONA AMAKURU N'INTEGO Z'UBUREZI.
Ibicuruzwa byatanzwe kururu rubuga bigenewe gusa mubushakashatsi bwa vitro. Mu bushakashatsi bwa vitro (Ikilatini: * mu kirahure *, bisobanura mu bikoresho by'ibirahure) bikorwa hanze y'umubiri w'umuntu. Ibicuruzwa ntabwo ari imiti, ntabwo byemejwe n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA), kandi ntigomba gukoreshwa mu gukumira, kuvura, cyangwa gukiza indwara iyo ari yo yose y’ubuvuzi, indwara, cyangwa indwara. Birabujijwe rwose n'amategeko kwinjiza ibyo bicuruzwa mumubiri wabantu cyangwa inyamaswa muburyo ubwo aribwo bwose.
Ku isi hose, umubyibuho ukabije wabaye ikibazo gikomeye cy’ubuzima rusange, gifitanye isano rya bugufi n’indwara zitandukanye zidakira nk’indwara zifata umutima ndetse na diyabete yo mu bwoko bwa 2, bigatuma gushakisha uburyo bunoze bwo kugabanya ibiro byibandwaho cyane mu bushakashatsi bw’ubuvuzi. Survodutide, nk'ibiyobyabwenge bishya, yerekanye imbaraga zishobora kugabanuka.
Incamake ya Survodutide
Survodutide nubushakashatsi bumaze igihe kirekire bukora agonist yibasiye icyarimwe yibasira reseptor ya glucagon imeze nka peptide-1 (GLP-1R) hamwe na glucose iterwa na insulineotropique polypeptide reseptor (GIPR). Bisaba ubuyobozi rimwe gusa mucyumweru, butanga abarwayi korohereza no kunoza uburyo bwo kuvura igihe kirekire.
Uburyo bwa Survodutide mugutakaza ibiro
Kugena Ingufu Zifata
Kurwanya ubushake bwo kurya: Nyuma yo gukora GLP-1R na GIPR, Survodutide ikorana na sisitemu yo hagati yo hagati kugirango igenzure hypothalamic appetit center. Gukora kwa GLP-1R ikora kuri fibre afferent fibre kugirango yohereze ibimenyetso kuri arcuate nucleus ya hypothalamus, ibuza ibikorwa bya neuron ya poroteyine (AgRP), Irashobora kandi gukora neuron ya proopiomelanocortin (POMC), bityo igatera kumva guhaga no kugabanya ibiryo. Gukora GIPR birashobora kandi kongera imbaraga zo kugabanya ubushake bwo kurya binyuze munzira zisa cyangwa zihuza imitsi, bityo bikagabanya ubushake bwumubiri kubiryo bityo bikagabanya gufata ingufu.
Guhindura ibiryo ukunda: Muburyo bwerekana umubyibuho ukabije na dyslipidemiya iterwa nimirire yubusa, Survodutide yagize ingaruka zidasanzwe kubyo bakunda ibiryo. Ugereranije nitsinda rishinzwe kugenzura, Survodutide yagabanije cyane gufata indyo yuzuye amavuta n’amazi akungahaye kuri fructose mugihe cyibyumweru 5 byo kuvura, mugihe nta ngaruka zigaragara zigira ku gufata ibiryo bisanzwe n'amazi asanzwe. Izi ngaruka zoguhitamo ibiryo bifasha kugabanya gufata ibiryo birimo kalori nyinshi, kugenzura imbaraga nyinshi ziva aho zituruka no gushyiraho urufatiro rwo kugabanya ibiro.
Kugena amafaranga akoreshwa
Guteza imbere okiside yibinure: Survodutide yerekana ingaruka zikomeye zoguhindura amavuta. Mugukoresha GLP-1R na GIPR, bigira ingaruka kumyanya mikorere ya selile binyuze munzira nyinshi zerekana. Itera lipolysis muri adipocytes, ikongera kurekura aside irike; aside irike irekuwe ijyanwa muri mitochondriya kugirango okiside, bityo ingufu zikoreshwa. Ubushakashatsi bwerekanye ko muburyo bwa vitro adipocyte, nyuma yo kuvura Survodutide, imisemburo yingenzi igira uruhare muri lipolysis hamwe na okiside ya aside irike, nka lipase yangiza imisemburo (HSL), karnitine palmitoyltransferase-1 (CPT-1), byerekana ko uburyo bwibikorwa byayo muguteza imbere amavuta ya metabolisme.
Kongera ingufu zikoreshwa: Usibye gukora ku buryo butaziguye ingirabuzimafatizo kugira ngo iteze imbere okiside, Survodutide irashobora kandi kongera ingufu mu gukoresha imbaraga za metabolism. Mu bushakashatsi bw’inyamaswa, byagaragaye ko mu gihe ibikorwa by’inyamaswa bidahindutse cyane nyuma y’ubuyobozi bwa Survodutide, igipimo cy’ibanze cya metabolike cyiyongereye. Ibi biterwa ningaruka ziterwa nibiyobyabwenge kumubiri ningingo nyinshi, byongera ibikorwa bya metabolike mumwijima no mumitsi ya skeletale, bityo bikongerera ingufu ingufu muburyo bwo kuruhuka no kugera kubutaka bwingufu, butera kugabanuka.
Kugenga glucose metabolism hamwe no kumva insuline
Kunoza insuline irwanya: abarwayi bafite umubyibuho ukabije bakunze kugira insuline irwanya insuline, igira ingaruka ku mbaraga zisanzwe no gukoresha. Survodutide ikora GLP-1R kugirango itume insuline isohoka mugihe yongera insuline, bityo umubiri ukongerera insuline. Mu bushakashatsi bwakozwe ku barwayi barwaye diyabete yo mu bwoko bwa 2, nyuma y’ibyumweru 16 bivurwa na Survodutide, urugero rwa plasma insuline hamwe n’igipimo cyo kurwanya insuline (HOMA-IR) cyaragabanutse ku buryo bugaragara, byerekana ko uyu muti ushobora kunoza insuline, bigatuma gufata neza selile no gukoresha glucose, kugabanya ihinduka ry’ibinure, no gufasha mu kugenzura ibiro.
Kugena urugero rwa glucose yamaraso: Igikorwa cya Survodutide ya reseptor agonist ikora itanga inyungu idasanzwe mugutunganya urugero rwamaraso glucose. GLP-1R agonism itera gusohora insuline mugihe ibuza glucagon kurekura, bityo bikagabanya urugero rwa glucose yamaraso. GIPR agonism itera kandi gusohora insuline mubihe byimiterere. Binyuze mu ngaruka zo guhuza imbaraga, birashobora gukomeza neza urugero rwa glucose rwamaraso. Urwego rwisukari rwamaraso ruhoraho rufasha kugabanya inzara no kongera ingufu ziterwa no guhindagurika kwisukari yamaraso, mu buryo butaziguye bigira ingaruka nziza mukugenzura ibiro.
Uruhare rwa Survodutide mugutakaza ibiro
Ingaruka zikomeye zo kugabanya ibiro: Mubigeragezo byateganijwe, impumyi ebyiri, igenzurwa na perezidansi yo mu cyiciro cya 2 ikigereranyo cyo gupima abarwayi bafite umubyibuho ukabije, abantu bakuru 387 bafite hagati yimyaka 18-75 bafite icyerekezo rusange cyumubiri (BMI) kg27 kg / m² kandi nta diyabete yashizwe mu matsinda atanu, yakira inshinge zo munsi ya Survodutide (0,6, 2.4, 3.6, cyangwa 4.8 mg) cyangwa umwanya wa mitiweli mugihe cyo kuvura ibyumweru 46. Ibisubizo byagaragaje ko mu cyumweru cya 46, abarwayi bavuwe na mg 4,8 za Survodutide bahuye n’ikigereranyo cyo kugabanya ibiro 18.7% ugereranije n’itsinda rya placebo, hamwe n’imibare itandukanye mu kugabanya ibiro. Mu bundi bushakashatsi bwibanze ku barwayi barwaye diyabete yo mu bwoko bwa 2 n'umubyibuho ukabije, ubuvuzi bwa Survodutide bwatumye ibiro bigabanuka bitewe n'imiti nyuma y'ibyumweru 16, bigabanuka cyane 8.7%. Byongeye kandi, Survodutide ku kigero cya .81.8 mg rimwe mu cyumweru yabyaye ibiro byinshi ugereranije na GLP-1 yakira reseptor agonist Semaglutid, bigatuma ibiro bigabanuka 5.3%.
Itandukaniro ry'uburinganire na BMI: Ubundi isesengura ryitsinda ryerekanye ko ingaruka zo kugabanya ibiro bya Survodutide zitandukanye mu bitsina bitandukanye no ku rwego rwa BMI. Mu igeragezwa ryavuzwe haruguru ryibasiye abarwayi bafite umubyibuho ukabije, ku cyumweru cya 46, impuzandengo yo kugabanya ibiro (17.0%) mu itsinda rya 4.8 mg Survodutide yari hejuru mu bagore kurusha abagabo (11.9%); mumatsinda atandukanye ya BMI, abarwayi bafite BMI <30 kg / m² yari afite igipimo cyo kugabanya ibiro byinshi (19.1%), ariko indangagaciro zo kugabanya ibiro ntizari zitandukanye cyane mumatsinda ya BMI. Ibi byerekana ko mubikorwa byubuvuzi, abaganga bashobora kugereranya neza ingaruka zo kugabanya ibiro bya Survodutide hashingiwe kubintu nkuburinganire bwabarwayi na BMI.
Ikwirakwizwa ryamavuta yumubiri no kunoza metabolike
Kugabanya ibinure bya visceral: Survodutide ntabwo igabanya uburemere bwumubiri gusa ahubwo inagira ingaruka nziza mukwirakwiza amavuta yumubiri. Kwiyegeranya cyane ibinure bya visceral bifitanye isano rya bugufi niterambere ryindwara zitandukanye. Mu bushakashatsi bujyanye n’ubushakashatsi, nyuma yo guhabwa imiti ya Survodutide mu gihe runaka, abarwayi bagabanutse cyane mu binure by’ibibyimba. Ni ukubera ko ibiyobyabwenge bitera gusenyuka no okiside yibinure byijimye, kunoza metabolisme bityo bikagabanya ingaruka ziterwa na metabolike zijyanye namavuta menshi yo mu mitsi.
Kunoza lipide idasanzwe: Abarwayi bafite umubyibuho ukabije bakunze kugira lipide idasanzwe, nka hypercholesterolemia na hypertriglyceridemia. Survodutide ntabwo ifasha gusa kugabanya ibiro ahubwo inatezimbere ibipimo bya lipide. Mu bushakashatsi bw’inyamaswa, hamsters ifite umubyibuho ukabije wavuwe na Survodutide yerekanye igabanuka rikabije rya plasma yuzuye ya cholesterol, aho kugabanuka kwa 41% mu itsinda rya Survodutide no kugabanuka kwa 24% mu itsinda rya semaglutide. Ibisubizo nkibi byagaragaye mubigeragezo byabantu, aho kuvura Survodutide byatumye igabanuka ryinshi rya triglyceride. Yagize kandi ingaruka zitandukanye zingaruka zubuyobozi kuri cholesterol ya lipoprotein nkeya (LDL-C) hamwe na cholesterol ya lipoprotein yuzuye (HDL-C), ifasha gukosora dyslipidemiya no kugabanya ibyago byindwara zifata umutima.
Ingaruka ku mpamvu ziterwa n'ingaruka z'umutima
Kugabanya umuvuduko w'amaraso: Umubyibuho ukabije ni kimwe mu bintu nyamukuru bitera umuvuduko ukabije w'amaraso. Mu bigeragezo bivura byibasiye abarwayi bafite umubyibuho ukabije, nyuma y'ibyumweru 46 bivurwa na Survodutide, umuvuduko w'amaraso wa sisitemu (SBP) n'umuvuduko w'amaraso wa diastolique (DBP) wagabanutse cyane. Ugereranije nitsinda rya placebo, itsinda rya 4.8 mg Survodutide ryerekanye igabanuka ntarengwa rya 10.2 mmHg muri SBP na 4.8 mmHg muri DBP. Izi ngaruka zo kugabanya umuvuduko wamaraso zishobora kuba zifitanye isano nimpamvu nyinshi, zirimo Survodutide kunoza imikorere yimitsi iva mumitsi, kugabanya ibikorwa byimitsi yimpuhwe, no kugabanya ibiro, bifasha hamwe kugabanya ibyago byindwara zifata umutima.
Kunoza imikorere y'amaraso: Survodutide irashobora kandi kugira ingaruka zo kurinda sisitemu yumutima nimiyoboro yimitsi mugutezimbere imikorere ya selile endoteliyale. Nyuma yubuyobozi bwa Survodutide, kurekura aside nitide (OYA) na selile endothelia selile yiyongera. OYA ni vasodilator yingenzi yagura imiyoboro yamaraso, igabanya kurwanya imitsi, kandi igatembera neza mumaraso. Uyu muti urashobora kandi kubuza kwifata no guhagarika umutima, bityo bikagabanya kwangirika kwinkuta zamaraso no gukomeza ubuzima bwimitsi.
Gukoresha Survodutide mugutakaza ibiro
Intego y'abaturage
Abantu bafite umubyibuho ukabije n'umubyibuho ukabije: Kubantu bafite umubyibuho ukabije cyangwa ufite ibiro byinshi bafite BMI kg 27 kg / m², Survodutide yerekanye ingaruka nziza zo kugabanya ibiro. Abarwayi bombi bafite umubyibuho ukabije hamwe n’abafite umubyibuho ukabije baherekejwe n’izindi ndwara ziterwa na metabolike nka diyabete yo mu bwoko bwa 2 cyangwa dyslipidemiya barashobora kungukirwa no kuvura Survodutide. Mu bigeragezo bivura, abarwayi bafite umubyibuho ukabije mu byiciro bitandukanye (imyaka 18-75) bagaragaje ibisubizo byiza kuri Survodutide, byerekana umubare munini wabaturage bujuje ibisabwa.
Abarwayi bafite umubyibuho ukabije ujyanye n'indwara zihariye: Usibye abaturage bafite umubyibuho ukabije muri rusange, Survodutide kandi ni uburyo bwo kuvura umubyibuho ukabije uterwa n'indwara zihariye, nka syndrome ya polycystic ovary syndrome (PCOS), aho umubyibuho ukabije n'indwara ziterwa na metabolike bikunze kubana.
Kugirango urusheho kongera ingaruka zo kugabanya ibiro no kunoza imiterere ya metabolike, Survodutide irashobora gukoreshwa hamwe nubundi buryo bwo kuvura. Iyo uhujwe nuburyo bwo kubaho (kugenzura imirire no gukora siporo), ingaruka zo guhuza imbaraga zirashobora kugerwaho. Mu bigeragezo bivura, abarwayi bahawe imiti ya Survodutide hamwe nimyitozo ngororamubiri isanzwe hamwe nimirire yuzuye bahuye nibiro byinshi ndetse niterambere ryinshi mubimenyetso bya metabolike. Byongeye kandi, ku barwayi barwaye diyabete yo mu bwoko bwa 2 n'umubyibuho ukabije, Survodutide irashobora gukoreshwa ifatanije n'indi miti igabanya ubukana nka metformin kugira ngo igabanye urugero rw'isukari mu maraso mu gihe igera ku micungire myiza y'ibiro.
Umwanzuro
Muri make, Survodutide, nkibintu bishya byakira reseptor agonist, ni ingirakamaro mu kugabanya ibiro. Uburyo bwihariye bwibikorwa ntibugabanya neza ibiro gusa ahubwo binatezimbere ikwirakwizwa ryamavuta yumubiri, bigenga glucose na lipide metabolism, kandi bigabanya ingaruka ziterwa numutima.
Inkomoko
[1] Briand F, Augustin R, Bleymehl K, n'abandi. 7279 Survodutide na Semaglutid Byombi Bitera Kugabanuka Ibiro ariko Byerekana Ingaruka Zinyuranye Kubikunda Ibiryo na Dyslipidemiya muburyo bwo guhitamo kubuntu Diet iterwa na Obese Hamster Model [J]. Ikinyamakuru cya Sosiyete Endocrine, 2024,8 (Umugereka_1): bvae134-bvae163.DOI: 10.1210 / jendso / bvae163.034.
[2] Le Roux C, Steen O, Lucas KJ, n'abandi. Survodutide, reseptor ya glucagon / GLP-1 reseptor (GCGR / GLP-1R) ebyiri agonist, itezimbere ibipimo byumutima byumutima kubantu bakuze bafite umubyibuho ukabije: isesengura ryibibanza bigenzurwa na platbo, byateganijwe mugice cya 2 [J]. Ikinyamakuru Umutima wiburayi, 2024,45 (Umugereka_1): ehae666-ehae2895.DOI: 10.1093 / eurheartj / ehae666.2895.
[3] Blüher M, Rosenstock J, Hoefler J, n'abandi. Ingaruka zifatika kuri HbA (1c) no kugabanya ibiro bya survodutide, glucagon ebyiri / GLP-1 reseptor agonist, ugereranije na placebo na semaglutide ifunguye abantu bafite diyabete yo mu bwoko bwa 2: kwipimisha kwa muganga [J]. Diyabete, 2024,67 (3): 470-482.DOI: 10.1007 / s00125-023-06053-9.
[4] Mei Z, Pu J, Shao Z. Ibigeragezo bibiri byo kuvura MASH hamwe na Fibrosis y'umwijima [J]. Ikinyamakuru gishya cy’ubuvuzi cy’Ubwongereza, 2024,391 (15): 1461-1462.DOI: 10.1056 / NEJMc2411003.
[5] Sanyal AJ, Bedossa P, Fraessdorf M, n'abandi. Icyiciro cya 2 Ikigeragezo cyemewe cya Survodutide muri MASH na Fibrosis [J]. Ikinyamakuru gishya cy’ubuvuzi cy’Ubwongereza, 2024,391 (4): 311-319.DOI: 10.1056 / NEJMoa2401755.
[6] Le Roux CW, Steen O, Lucas KJ, n'abandi. Glucagon na GLP-1 reseptor dual agonist survodutide kubera umubyibuho ukabije: umuntu utabishaka, impumyi ebyiri, igenzurwa na platbo, ikizamini cyo gushakisha icyiciro cya 2. Lancet. Diyabete & Endocrinology, 2024. Https://api.semanticscholar.org/CorpusID:267503510
[7] Lawitz EJ, Fraessdorf M, Neff GW, n'abandi. OS-119 Survodutide (BI 456906), reseptor ya glucagon / glucagon isa na peptide-1 yakira (GCGR / GLP-1R) agonist ebyiri, mubantu bafite cirrhose yishyuwe kandi yangiritse: ibihugu byinshi, bifunguye-label, ikigeragezo cya 1 [J]. Ikinyamakuru cya Hepatology, 2024.
[8] Le Roux CW, Steen O, Lucas KJ, n'abandi. 6926 Isesengura ryitsinda ryakozwe nuburinganire nuburinganire bwumubiri (BMI) mubantu babana nuburemere burenze / Umubyibuho ukabije muri Survodutide, Glucagon / GLP-1 Receptor Dual Agonist, Ikiciro cya II [J]. Ikinyamakuru cya Sosiyete Endocrine, 2024,8 (Umugereka_1): bvae133-bvae163.DOI: 10.1210 / jendso / bvae163.033.
Ibicuruzwa biboneka mubushakashatsi bukoreshwa gusa:
